HOPE RICHARDSON: Open Payments
NPI 1053044917 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 24 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $316 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $164 |
| Novo Nordisk Inc | 5 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $87 |
| ABBVIE INC. | 3 | $57 |
| Sage Therapeutics, LLC | 3 | $56 |
| Amgen Inc. | 2 | $46 |
| Organon LLC | 2 | $43 |
| Lilly USA, LLC | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: Veozah, CAPLYTA, Ozempic, ZURZUVAE, OTEZLA, VRAYLAR, NEXPLANON, Wegovy.
Industry payments across TN — which companies pay providers there.
